Overexpression and Selective Anticancer Efficacy of in Mutant Lung Cancers.

Oncogenic gain-of-function mutations are clinical biomarkers for most targeted therapies, as well as represent direct targets for drug treatment. Although loss-of-function mutations involving the tumor suppressor gene, are important in lung cancer progression, is not the direct target for anticancer agents. We attempted to identify cancer transcriptome signatures associated with loss-offunction mutations.